Hilton Hotel, Athens,
1 – 4 /11/2018

 

IΑSIS PHARMA  successfully participated in the 14th Panhellenic Conference for Dermatology, organized by the Hellenic Society of Dermatology and Venereology (EDAE), at Hilton Hotel Athens, November 1st-4th 2018.

The Conference updated the Dermatologists on the latest scientific developments on diseases such as Psoriasis, Acne, Melanoma, Connective Tissue Diseases, Nail and Hair Diseases and more.
A large number of Dermatologists visited IASIS PHARMA exhibition stand, where two (2) of its main Dermatological products were highlighted.

Health specialists were highly interested in Modiwart®, with imiquimod as its active ingredient.
Modiwart® is an innovative immunomodulator, with the following indications:
• external genital and anogenital warts (condyloma acuminata) in adults.
• small superficial basal cell carcinomas (sBCCs).
• clinically typical actinic keratosis.
Modiwart® is available as a cream (5%) for topical use, in single-use sachets (12 per package).

IASIS PHARMA also exhibited one of its most well-established product: Ιsotroin®, isotretinoin.
It is a retinoid for the treatment of acne, the only product of its kind in the Greek market available in soft caps of 10mg, 20mg and 40mg strength, thus helping the dermatologist to ideally customize the required dosage per patient.

 

panell-derm-18final